Vertex CF Combo Succeeds In Phase III, But Secondary Endpoints May Be Crucial
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
Vertex’s two-drug combo for cystic fibrosis hits primary and several key secondary endpoints in a pair of pivotal trials, although data from the primary endpoint underwhelms some observers. Strong data from a pair of secondary endpoints, however, may provide real-world strategic value for the combo.
You may also be interested in...
Vertex Phase III For CF Combo Shows Power Of “Breakthrough” Designation
Pivotal trials for the combination of Kalydeco and VX-809 will measure safety and efficacy over 24 weeks, whereas Kalydeco monotherapy gained FDA approval on the basis of 56 weeks of data; Vertex and FDA developed the protocol together following a recent “breakthrough therapy” designation for the two-drug combo.
Cosmetic And Personal Care Trademark Review: 16 April
Personal care and cosmetic product trademark filings compiled from the Official Gazette of the US Patent and Trademark Office, Class 3.
Health And Wellness Weekly Trademarks Review: 16 April
Trademarks are registered and published for opposition with the US Patent and Trademark Office and are published weekly in the agency's Official Gazette.